Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €116.77 EUR
Change Today +0.23 / 0.20%
Volume 1.1K
VX1 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
As of 10:30 AM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

50 Northern Avenue

Boston, MA 02210

United States

Phone: 617-341-6100

Fax:

d in future dual- and/or triple-combination treatment regimens with the potential to provide additional benefits to patients with CF. The company has multiple next-generation correctors in the lead-optimization stage of research and expects to begin clinical development of a next-generation corrector in 2015. Hepatitis C Virus (HCV) Infection INCIVEK (telaprevir) is an orally-administered HCV protease inhibitor for adults with genotype 1 HCV infection that was prescribed in combination with pegylated-interferon and ribavirin. INCIVEK achieved acceptance for the treatment of patients with genotype 1 HCV infection in the United States. The company’s collaborators, Janssen Pharmaceutica NV and Mitsubishi Tanabe Pharma Corporation, retain fully-paid licenses to telaprevir and market telaprevir in their respective territories. Research and Early-stage Development Programs The company engages in various other research and early-stage development programs, including programs in the areas of oncology and neurology. The company’s platform integrates genetics, biology, pharmacology, drug metabolism and pharmacokinetics, toxicology, material sciences, biophysics, medicinal chemistry and process chemistry, automation, and information technologies in a coordinated fashion throughout the discovery process. The company focuses its research activities on products that would be prescribed by specialist physicians for the treatment of rare or life-threatening diseases, which are referred to as specialty markets. The company’s drug discovery efforts have produced various drug candidates that have been commercialized or are in preclinical or clinical development. In oncology, the company is developing VX-803 and VX-970, which are designed to regulate the repair of damaged DNA within cancer cells through inhibition of a protein kinase known as ATR. The company is evaluating VX-803 and VX-970 in open-label, Phase 1 clinical trials in patients with advanced solid tumors. It expects to initiate clinical development for one or more additional compounds from its research programs in 2015. To augment the company’s internal research programs, it intends to collaborate with major academic research institutions, government laboratories, foundations, and other organizations to advance research in its areas of therapeutic interest, as well as in areas of basic technological enablement. Collaborations The company has a collaboration agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (CFFT) to support research and development activities related to potentiator compounds and corrector compounds, including ivacaftor, lumacaftor, and VX-661. The company retains worldwide rights to develop and commercialize ivacaftor, lumacaftor, VX-661 and any other compounds discovered during the course of the research collaboration with CFFT. In October 2014, the company entered into a license and collaboration agreement with BioAxone Biosciences, Inc. (BioAxone), a privately-held biotechnology company. Pursuant to this agreement, the company is collaborating with BioAxone on the research, development, and commercialization of VX-210, a biologic controlled by BioAxone, for the treatment of patients with spinal cord injuries. VX-210 has been evaluated as a single dose application in an open-label, non-placebo controlled Phase 1/2a clinical trial at multiple doses in 48 patients with thoracic and cervical acute spinal cord injuries. In 2014, the company entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen Inc.). Pursuant to this agreement, Janssen Inc. has a worldwide license to develop and commercialize certain drug candidates for the treatment of influenza, including VX-787. Intellectual Property Vertex, KALYDECO, and INCIVEK are registered trademarks of the company. Its intellectual property holdings comprise: The U.S. and foreign patent applications covering potentiator compounds and corrector compounds for the CFTR protein, including ivacaftor, lumacaftor and VX-661 and various other related compounds, and the use of those potentiators and correctors to treat CF. The U.S. and foreign patent

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VX1:GR €116.77 EUR +0.23

VX1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $60.02 USD -0.55
BioMarin Pharmaceutical Inc $127.46 USD -2.08
Incyte Corp $108.44 USD +0.52
Jazz Pharmaceuticals PLC $178.96 USD -0.46
View Industry Companies
 

Industry Analysis

VX1

Industry Average

Valuation VX1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 49.9x
Price/Book 31.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 47.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERTEX PHARMACEUTICALS INC, please visit www.vrtx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.